Truist lowered the firm’s price target on Intuitive Surgical (ISRG) to $605 from $666 but keeps a Buy rating on the shares. Tariffs may be a near-term earnings headwind, but a manageable one, the analyst tells investors in a research note. Intuitive Surgical is also better positioned on historical basis to grow through a potential capex slowdown, Truist notes, adding that long-term investors will typically come back to this stock on macro-driven pullbacks.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical Positioned for Growth Amidst Rising Adoption of Robotic Surgeries
- Intuitive Surgical’s Strong Market Position and Technological Advancements Justify Buy Rating
- Tariff delay positive for Mexico-exposed medtech companies, says BofA
- Intuitive Surgical: Buy Rating Backed by Stable Surgery Volumes and Innovative Robotic Systems
- ISRG, SOFI, or MU: Which Growth Stock Could Deliver the Highest Returns?
Questions or Comments about the article? Write to editor@tipranks.com